Cargando...
A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma
Even though the prognosis of patients with multiple myeloma is continuing to improve, all patients eventually develop relapsed refractory disease. Several novel therapeutics have been developed in the last few years including the second-generation proteasome inhibitor carfilzomib which has been appr...
Gardado en:
| Publicado en: | Ther Adv Hematol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publications
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5089326/ https://ncbi.nlm.nih.gov/pubmed/27904737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716667275 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|